Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
The global image-guided drug delivery (IGDD) market is revolutionizing modern medicine by combining advanced imaging with ...
AIC, a division of AIS Healthcare, now offers YIMMUGO®, manufactured by Kedrion Biopharma, for the treatment of primary humoral immunodeficiency in patients 2 years of age and older.
The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), a new drug-device combination developed by SQ Innovation, Inc., for treating edema caused by chronic heart ...
The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult ...
The device, called SPIRAL (Strategic Precision Infusion for Regional Administration of Liquid), is a thin, flexible tube designed to release medication at several points inside the brain. Courtesy NYU ...
(Alliance News) - AstraZeneca PLC on Friday said Saphnelo subcutaneous self-administration has been recommended for approval in the European Union for systemic lupus erythematosus.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback